Principal Financial Group Inc Xencor Inc Transaction History

Principal Financial Group Inc

  • $172 Billion
  • Q3 2024

A detailed history of Principal Financial Group Inc transactions in Xencor Inc stock. As of the latest transaction made, Principal Financial Group Inc holds 291,916 shares of XNCR stock, worth $7.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
291,916
Previous 307,167 4.97%
Holding current value
$7.3 Million
Previous $5.81 Million 0.96%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024
SELL
$15.7 - $21.65 $239,440 - $330,184
-15,251 Reduced 4.97%
291,916 $5.87 Million
Q2 2024

Jul 29, 2024
SELL
$18.21 - $24.5 $300,428 - $404,201
-16,498 Reduced 5.1%
307,167 $5.81 Million
Q1 2024

Apr 29, 2024
SELL
$18.65 - $26.52 $342,134 - $486,509
-18,345 Reduced 5.36%
323,665 $7.16 Million
Q4 2023

Feb 07, 2024
SELL
$16.53 - $21.42 $67,888 - $87,971
-4,107 Reduced 1.19%
342,010 $7.26 Million
Q3 2023

Nov 02, 2023
SELL
$20.08 - $25.39 $269,694 - $341,013
-13,431 Reduced 3.74%
346,117 $6.97 Million
Q2 2023

Aug 07, 2023
SELL
$24.77 - $29.9 $413,881 - $499,599
-16,709 Reduced 4.44%
359,548 $8.98 Million
Q1 2023

May 09, 2023
SELL
$25.95 - $36.95 $150,639 - $214,494
-5,805 Reduced 1.52%
376,257 $10.5 Million
Q4 2022

Feb 09, 2023
BUY
$24.79 - $30.86 $195,022 - $242,775
7,867 Added 2.1%
382,062 $9.95 Million
Q3 2022

Nov 09, 2022
BUY
$24.62 - $32.44 $10,758 - $14,176
437 Added 0.12%
374,195 $9.72 Million
Q2 2022

Aug 10, 2022
SELL
$19.74 - $29.01 $570,367 - $838,214
-28,894 Reduced 7.18%
373,758 $10.2 Million
Q1 2022

May 09, 2022
SELL
$26.68 - $41.63 $82,041 - $128,012
-3,075 Reduced 0.76%
402,652 $10.7 Million
Q4 2021

Feb 09, 2022
SELL
$33.67 - $43.44 $510,740 - $658,941
-15,169 Reduced 3.6%
405,727 $16.3 Million
Q3 2021

Nov 09, 2021
SELL
$30.65 - $35.68 $127,136 - $148,000
-4,148 Reduced 0.98%
420,896 $13.7 Million
Q2 2021

Aug 10, 2021
BUY
$34.33 - $44.68 $87,198 - $113,487
2,540 Added 0.6%
425,044 $14.7 Million
Q1 2021

May 10, 2021
BUY
$40.81 - $53.88 $80,558 - $106,359
1,974 Added 0.47%
422,504 $18.2 Million
Q4 2020

Feb 08, 2021
SELL
$36.63 - $47.63 $326,629 - $424,716
-8,917 Reduced 2.08%
420,530 $18.3 Million
Q3 2020

Nov 06, 2020
BUY
$30.09 - $43.02 $1.13 Million - $1.62 Million
37,612 Added 9.6%
429,447 $16.7 Million
Q2 2020

Aug 05, 2020
BUY
$27.76 - $33.42 $247,064 - $297,438
8,900 Added 2.32%
391,835 $12.7 Million
Q1 2020

May 12, 2020
SELL
$20.69 - $37.79 $442,310 - $807,874
-21,378 Reduced 5.29%
382,935 $11.4 Million
Q4 2019

Feb 05, 2020
SELL
$32.75 - $41.43 $4,978 - $6,297
-152 Reduced 0.04%
404,313 $13.9 Million
Q3 2019

Nov 13, 2019
BUY
$33.73 - $46.27 $13.2 Million - $18 Million
389,886 Added 2674.3%
404,465 $13.6 Million
Q2 2019

Aug 12, 2019
BUY
$29.6 - $40.93 $180,412 - $249,468
6,095 Added 71.84%
14,579 $597,000
Q1 2019

May 10, 2019
SELL
$27.85 - $38.09 $157,547 - $215,475
-5,657 Reduced 40.0%
8,484 $264,000
Q4 2018

Feb 14, 2019
SELL
$32.39 - $42.05 $63,613 - $82,586
-1,964 Reduced 12.19%
14,141 $512,000
Q3 2018

Nov 14, 2018
BUY
$35.69 - $47.65 $82,301 - $109,880
2,306 Added 16.71%
16,105 $628,000
Q2 2018

Aug 13, 2018
BUY
$28.41 - $42.41 $152,419 - $227,529
5,365 Added 63.61%
13,799 $0
Q1 2018

May 14, 2018
BUY
$21.18 - $33.78 $178,632 - $284,900
8,434 New
8,434 $253,000
Q4 2017

Feb 13, 2018
SELL
$19.29 - $24.83 $169,559 - $218,255
-8,790 Closed
0 $0
Q3 2017

Nov 02, 2017
BUY
$19.61 - $23.35 $172,371 - $205,246
8,790
8,790 $201,000

Others Institutions Holding XNCR

# of Institutions
215
Shares Held
71.8M
Call Options Held
2.5K
Put Options Held
7.9K
View Full List

About Xencor Inc

XNCR Quotes by TradingView
  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.49B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email